Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)
China · Delayed Price · Currency is CNY 5.75
-0.15 (-2.54%)
Sep 10, 2026, 12:44 PM CST
Beijing SL Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 762.59 | 519.4 | 411.96 | 683.83 | 595.04 | 827.84 |
Short-Term Investments | - | 122.98 | 1,089 | 840.62 | 713.36 | 646.23 |
Trading Asset Securities | 473.02 | 498.95 | 480.86 | 608.56 | 144.91 | 162.36 |
Cash & Short-Term Investments | 1,236 | 1,141 | 1,982 | 2,133 | 1,453 | 1,636 |
Cash Growth | -35.55% | -42.42% | -7.07% | 46.77% | -11.19% | 13.41% |
Accounts Receivable | 76.06 | 80.93 | 105.79 | 200.57 | 254.86 | 357.56 |
Other Receivables | 8.85 | 14.07 | 15.65 | 35.25 | 31.35 | 21.6 |
Receivables | 84.91 | 95 | 121.44 | 235.82 | 286.2 | 379.16 |
Inventory | 141.55 | 681.81 | 246.33 | 144.46 | 136.82 | 124.83 |
Other Current Assets | 109 | 175.82 | 138.8 | 126.69 | 121.34 | 157.31 |
Total Current Assets | 1,571 | 2,094 | 2,489 | 2,640 | 1,998 | 2,298 |
Property, Plant & Equipment | 524.55 | 541.53 | 514.24 | 503.34 | 527.3 | 604.01 |
Long-Term Investments | 1,267 | 1,878 | 1,578 | 1,573 | 1,798 | 1,404 |
Other Intangible Assets | 594.92 | 633.01 | 678.58 | 693.77 | 526.36 | 479.46 |
Long-Term Deferred Tax Assets | 50.24 | 53.7 | 69.52 | - | 39.5 | 27.65 |
Long-Term Deferred Charges | 515.02 | 503.88 | 519 | 451.89 | 454.42 | 394.72 |
Other Long-Term Assets | 751.39 | 367.93 | 130.49 | 415.6 | 532.22 | 553.25 |
Total Assets | 5,274 | 6,072 | 5,979 | 6,278 | 5,876 | 5,760 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 55.78 | 95.54 | 122.29 | 250.76 | 176.18 | 191.4 |
Accrued Expenses | 38.22 | 48.28 | 45.82 | 46.93 | 30.32 | 31.8 |
Current Portion of Leases | - | - | - | - | - | 0.25 |
Current Income Taxes Payable | 4 | 0.16 | 0.18 | 0 | 2.61 | 4.48 |
Current Unearned Revenue | 16.84 | 491.97 | 70.53 | 15.29 | 27.87 | 13.33 |
Other Current Liabilities | 87.07 | 93.64 | 50.59 | 60.34 | 51.85 | 83.71 |
Total Current Liabilities | 201.91 | 729.59 | 289.41 | 373.33 | 288.83 | 324.96 |
Long-Term Leases | - | - | - | - | - | 2.22 |
Long-Term Unearned Revenue | 73.8 | 41.07 | 44 | 47.04 | 51.38 | 56.23 |
Long-Term Deferred Tax Liabilities | 65.98 | 112.83 | 64.97 | 47.36 | 56.39 | 50.82 |
Total Liabilities | 341.69 | 883.49 | 398.37 | 467.72 | 396.6 | 434.23 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 1,027 | 1,027 | 1,027 | 1,027 | 1,027 | 1,027 |
Additional Paid-In Capital | 61.55 | 61.55 | 49.62 | 49.62 | 43.85 | 32.58 |
Retained Earnings | 3,859 | 4,114 | 4,482 | 4,710 | 4,396 | 4,265 |
Comprehensive Income & Other | -21.77 | -21.77 | 13.47 | 13.47 | 0.67 | -12.99 |
Total Common Equity | 4,926 | 5,181 | 5,572 | 5,801 | 5,468 | 5,311 |
Minority Interest | 6.46 | 7.19 | 8.2 | 9.42 | 11.16 | 14.73 |
Shareholders' Equity | 4,933 | 5,189 | 5,581 | 5,810 | 5,479 | 5,326 |
Total Liabilities & Equity | 5,274 | 6,072 | 5,979 | 6,278 | 5,876 | 5,760 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | - | - | - | - | - | 2.47 |
Net Cash (Debt) | 1,236 | 1,141 | 1,982 | 2,133 | 1,453 | 1,634 |
Net Cash Growth | -35.55% | -42.42% | -7.07% | 46.77% | -11.06% | 13.67% |
Net Cash Per Share | 1.20 | 1.12 | 1.87 | 2.10 | 1.43 | 1.57 |
Filing Date Shares Outstanding | 964.17 | 1,027 | 1,027 | 1,027 | 1,027 | 1,027 |
Total Common Shares Outstanding | 964.17 | 1,027 | 1,027 | 1,027 | 1,027 | 1,027 |
Working Capital | 1,369 | 1,364 | 2,199 | 2,267 | 1,709 | 1,973 |
Book Value Per Share | 5.11 | 5.04 | 5.42 | 5.65 | 5.32 | 5.17 |
Tangible Book Value | 4,331 | 4,548 | 4,894 | 5,107 | 4,942 | 4,832 |
Tangible Book Value Per Share | 4.49 | 4.43 | 4.76 | 4.97 | 4.81 | 4.70 |
Buildings | - | 447.97 | 434.54 | 437.22 | 430.73 | 452.32 |
Machinery | - | 485.36 | 472.98 | 458.48 | 435.39 | 415.76 |
Construction In Progress | - | 135.02 | 94.92 | 56.97 | 64.75 | 99.87 |